

APPLICANT(S): WALDMANN, Herman
SERIAL NO.: 09/849,499
FILED: May 04, 2001
Page 8

CLAIM REJECTIONS

35 U.S.C. § 112 Rejections

In the Office Action, the Examiner rejected claims 64, 68-95, 105-108, 110, and 111 under 35 U.S.C. § 112, first paragraph because they allegedly do not provide enablement for producing long-term cultures of immature dendritic cells utilizing any population of ES cells.

Further, the Examiner admitted that the specification and the Declaration provide an enabling disclosure only for culturing mouse or human ES cells in the presence of IL-3 to produce immature dendritic cells whereas the scope of the subject claims is far broader, encompassing any dendritic cell derived from any ES cell.

In response, Applicants respectfully assert that the amendments, directing, claim 64 to human and mouse render claims 64, 68-95, 105-108, 110, and 111 proper under 35 USC 112 and request that the rejections be withdrawn.

In view of the foregoing amendments and remarks, the pending claims are deemed to be allowable. Their favorable reconsideration and allowance is respectfully requested.


Should the Examiner have any question or comment as to the form, content or entry of this Amendment, the Examiner is requested to contact the undersigned at the telephone number below. Similarly, if there are any further issues yet to be resolved to advance the prosecution of this application to issue, the Examiner is requested to telephone the undersigned counsel.

CONFIDENTIAL

APPLICANT(S): WALDMANN, Herman
SERIAL NO.: 09/849,499
FILED: May 04, 2001
Page 9

Please charge any fees associated with this paper to deposit account No. 50-3355.

Respectfully submitted,



Mark S. Cohen
Attorney/Agent for Applicant(s)
Registration No. 42425

Dated: November 23, 2005

Pearl Cohen Zedek Latzer, LLP
10 Rockefeller Plaza, Suite 1001
New York, New York 10020
Tel: (212) 632-3480
Fax: (212) 632-3489

CONFIDENTIAL